AOD-9604 vs GLP-3 RTA
AOD-9604 and GLP-3 RTA are both studied in weight research, but they are different classes of compound with different reported research applications.
✓ both US-made · third-party tested · batch COA on every order
Last updated August 25, 2026
How do AOD-9604 and GLP-3 RTA differ?
AOD-9604 (Modified human growth hormone fragment) is catalogued under weight & metabolic research; GLP-3 RTA (Synthetic triple-agonist peptide) is catalogued under weight & metabolic research. Verve lists 5 reported research applications for AOD-9604 and 5 for GLP-3 RTA. Both are made in the United States, screened by HPLC to a 99%+ purity standard, and shipped with a batch-level certificate of analysis.
| field | AOD-9604 | GLP-3 RTA |
|---|---|---|
| compound class | Modified human growth hormone fragment | Synthetic triple-agonist peptide |
| research area | weight & metabolic | weight & metabolic |
| reported research applications | 5 listed | 5 listed |
| supplied as | single compound | single compound |
| catalog sizes | 10mg | 10mg · 20mg · 30mg |
| purity standard | 99%+ by HPLC | 99%+ by HPLC |
| manufactured | United States | United States |
| batch COA | published per lot | published per lot |
| endotoxin-tested option | not offered | available |
| co-formulated together in | not co-formulated | not co-formulated |
| price from | $114.49 | $142.99 |
| availability | out of stock | in stock |
Prices and stock read live from the catalog. Both compounds are supplied strictly as reference materials for in-vitro laboratory research.
What is AOD-9604 and what is GLP-3 RTA?
AOD-9604 is classified as Modified human growth hormone fragment; GLP-3 RTA as Synthetic triple-agonist peptide. Both profiles below cover scientific identity only — what the molecule is and which laboratory models it appears in. Verve supplies both strictly as in-vitro reference materials, and neither profile describes human or veterinary use.
AOD-9604
Modified human growth hormone fragment
AOD-9604 is a synthetic peptide corresponding to the C-terminal 176–191 fragment of human growth hormone, modified by the addition of a tyrosine residue at the N-terminus to improve stability. Unlike the full-length hormone, the fragment lacks the regions associated with growth-hormone receptor binding, which is what makes it useful as a dissociated structural probe in research.
full AOD-9604 profile →GLP-3 RTA
Synthetic triple-agonist peptide
GLP-3 RTA is a synthetic single-chain peptide engineered to act at three related class B G-protein-coupled receptors at once: the GLP-1 receptor, the GIP receptor, and the glucagon receptor. Its backbone is derived from the incretin peptide family and carries a fatty-acid modification that extends plasma half-life in pre-clinical systems, making it a widely cited reference agonist in incretin-receptor research.
full GLP-3 RTA profile →Which research models is each compound studied in?
AOD-9604 and GLP-3 RTA both sit inside weight & metabolic research, so their listed models share framing while differing in specifics. The table lists 5 reported research applications for AOD-9604 and 5 for GLP-3 RTA. Rows are per compound, not equivalences.
| AOD-9604 — reported research applications | GLP-3 RTA — reported research applications |
|---|---|
| Lipid-metabolism and adipocyte-signaling research models | GLP-1, GIP, and glucagon receptor agonism research |
| Growth-hormone fragment structure–activity research | cAMP and class B GPCR signaling research models |
| Lipolytic and lipogenic enzyme pathway studies | Comparative single-, dual-, and triple-agonist pharmacology studies |
| Comparative studies against full-length growth hormone | Metabolic-pathway and nutrient-handling research models |
| Body-composition research endpoints in pre-clinical models | Peptide half-life, lipidation, and stability research |
Research contexts only. Both compounds are supplied for laboratory research use only, and no entry above describes an effect in humans or animals.
What sizes and prices does verve list for AOD-9604 and GLP-3 RTA?
AOD-9604 is listed from $114.49 and GLP-3 RTA from $142.99. The table below is every catalog size verve currently lists for the two compounds, at single-vial prices before the automatic multi-compound discount. Sizes describe the vial format supplied to the laboratory, nothing more.
| compound | size listed | price | availability |
|---|---|---|---|
| AOD-9604 | 10mg | $114.49 | out of stock |
| GLP-3 RTA | 10mg | $142.99 | in stock |
| GLP-3 RTA | 20mg | $242.99 | in stock |
| GLP-3 RTA | 30mg | $328.99 | in stock |
Any 2 different compounds take 20% off, any 3 take 30% — applied automatically in the cart, no code. Orders placed Monday–Friday ship by 2pm CT, free over $100.
shop the compounds →Frequently asked questions about AOD-9604 and GLP-3 RTA
What is AOD-9604?
AOD-9604 is a synthetic peptide based on the 176–191 C-terminal fragment of human growth hormone, with an added N-terminal tyrosine. Verve supplies it as a research compound for laboratory use only, not for human or veterinary use.
What is AOD-9604 studied for in research?
It is used as a reference compound in lipid-metabolism, adipocyte-signaling, and enzyme-pathway research, and in structure–activity studies comparing fragments to full-length growth hormone. Verve makes no claims about use in humans or animals.
What is GLP-3 RTA?
GLP-3 RTA is a synthetic peptide that acts as an agonist at three receptors — GLP-1, GIP, and glucagon. Verve supplies it as a research compound for laboratory use only, not for human or veterinary use.
What is GLP-3 RTA studied for in research?
In in-vitro and pre-clinical models it is used as a reference agonist in incretin-receptor pharmacology, cAMP signaling, and metabolic-pathway research. Verve makes no claims about use in humans or animals.
related comparisons
verve products are sold for laboratory research and development purposes only and are not intended for human or veterinary use of any kind. statements on this site have not been evaluated by the FDA.